ALC - Editas trades higher after bullish rating; Alcon upgrade at BTIG in today's analyst calls

Editas Medicine (EDIT) is trading ~3.8% higher in pre-market hours after Credit Suisse initiated coverage with an outperform rating. The price target of $58.00 per share indicates an upside of ~28.9% to the previous close.Analyst Tiago Fauth argues that the company is a pioneer in CRISPR gene editing which according to the analyst could potentially be a single-dose treatment for a range of diseases including blindness and cancer.In late February, Truist lowered its rating on Editas to hold from buy noting among others the recent leadership changes at the company.BTIG analyst Ryan Zimmerman has upgraded Alcon (ALC) to buy from neutral with the price target of ~$78.00 per share indicating ~14.5% upside to the previous close. The shares are up ~0.8% in the before hours.Citing expert views and surveys, the analyst opines that the company is a beneficiary in post-pandemic ‘recovery dynamics’ and expects its management to address the concerns over the long-term targets

For further details see:

Editas trades higher after bullish rating; Alcon upgrade at BTIG in today’s analyst calls